ACADIA PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net income | $35,137 | $45,653 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 31,638 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | (503) | (3,652) |
| Amortization of intangible assets | 5,445 | 5,444 |
| Depreciation | 705 | 442 |
| Deferred Income Taxes | 9,679 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (29,188) | (8,766) |
| Interest and other receivables | 11,080 | (6,225) |
| Inventory | 3,975 | (14,553) |
| Prepaid expenses and other current assets | (9,843) | 2,934 |
| Other assets | 346 | (1,306) |
| Operating lease right-of-use assets | 4,398 | 4,259 |
| Accounts payable | 33,666 | 3,905 |
| Accrued liabilities | 46,088 | 21,350 |
| Operating lease liabilities | (4,032) | (1,418) |
| Long-term liabilities | (3,829) | 10,492 |
| Net cash provided by operating activities | 134,762 | 84,279 |
| Cash flows from investing activities | ||
| Purchases of investment securities | (108,447) | (330,398) |
| Maturity of investment securities | 176,500 | 262,190 |
| Payment of milestone and contingent payments in connection with asset acquisition | — | (98,838) |
| Purchases of property and equipment | (10,301) | (297) |
| Net cash provided by (used in) investing activities | 57,752 | (167,343) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 14,725 | 17,794 |
| Net cash provided by financing activities | 14,725 | 17,794 |
| Effect of exchange rate changes on cash | 52 | 19 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 207,291 | (65,251) |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 185,540 | 328,359 |
| End of period | $392,831 | $263,108 |
| Supplemental disclosure of noncash information: | ||
| Accrued inventory purchases | $1,152 | $4,040 |
| Stock-based compensation capitalized | $122 | $308 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.